Literature DB >> 2049087

Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors.

H Muramatsu1, T Muramatsu.   

Abstract

Midkine (MK) is the product of a retinoic acid responsive gene, MK, and is the initial member of a new family of heparin binding factors. Recombinant MK produced by an L-cell clone transfected with an MK cDNA was purified to homogeneity. When rat embryonic brain cells were cultured in a serum-free medium on plastic dishes coated with purified MK, a number of neurites extended, formed networks and fasciculated. The majority of neurons continued to extend neurites for a week. In control cultures, neurite extension was observed only in a few cells. Neurotrophic activity of retinoic acid may be mediated by MK. MK had weak but significant mitogenic activity to 3T3 fibroblasts but not to NRK cells. Thus, MK and other members of the family share a part of the activities.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049087     DOI: 10.1016/0006-291x(91)91838-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

2.  Construction of a fusion protein expression vector MK-EGFP and its subcellular localization in different carcinoma cell lines.

Authors:  Li-Cheng Dai; Di-Yong Xu; Xing Yao; Li-Shan Min; Ning Zhao; Bo-Ying Xu; Zheng-Ping Xu; Yong-Liang Lu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

3.  Midkine promotes selective expansion of the nephrogenic mesenchyme during kidney organogenesis.

Authors:  Libo Qiu; Deborah P Hyink; William H Gans; Kurt Amsler; Patricia D Wilson; Christopher R Burrow
Journal:  Organogenesis       Date:  2004-07       Impact factor: 2.500

4.  Neointima formation in a restenosis model is suppressed in midkine-deficient mice.

Authors:  M Horiba; K Kadomatsu; E Nakamura; H Muramatsu; S Ikematsu; S Sakuma; K Hayashi; Y Yuzawa; S Matsuo; M Kuzuya; T Kaname; M Hirai; H Saito; T Muramatsu
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  Midkine, heparin-binding growth factor, blocks kainic acid-induced seizure and neuronal cell death in mouse hippocampus.

Authors:  Yun B Kim; Jae K Ryu; Hong J Lee; In J Lim; Dongsun Park; Min C Lee; Seung U Kim
Journal:  BMC Neurosci       Date:  2010-03-26       Impact factor: 3.288

6.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

7.  Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

8.  The growth factor midkine regulates the renin-angiotensin system in mice.

Authors:  Akinori Hobo; Yukio Yuzawa; Tomoki Kosugi; Noritoshi Kato; Naoto Asai; Waichi Sato; Shoichi Maruyama; Yasuhiko Ito; Hiroyuki Kobori; Shinya Ikematsu; Akira Nishiyama; Seiichi Matsuo; Kenji Kadomatsu
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

9.  Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Authors:  Misato Takagi-Kimura; Tomoki Yamano; Atsuko Tamamoto; Nobutaka Okamura; Haruki Okamura; Tomoko Hashimoto-Tamaoki; Masatoshi Tagawa; Noriyuki Kasahara; Shuji Kubo
Journal:  Cancer Sci       Date:  2013-09-23       Impact factor: 6.716

10.  A retinoid responsive cytokine gene, MK, is preferentially expressed in the proximal tubules of the kidney and human tumor cell lines.

Authors:  M Kitamura; T Shirasawa; T Mitarai; T Muramatsu; N Maruyama
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.